Steve F. Urvan, age 59, serves as our Chief Executive Officer and Chairman of the Board. Effective May 30, 2025, Mr. Urvan was appointed as the Chief Executive Officer and as the Chairman of the Board of Directors. Mr. Urvan owns or controls approximately 14.8% of our Common Stock as of the Record Date, including 17,242,857 shares of common stock held by Balentine, LLC that may be deemed to be beneficially owned by Mr. Urvan. Mr. Urvan is not an independent director as defined by the Nasdaq listing standards, as he is and has been employed by the Company within the past three years. For the year ended March 31, 2025, Mr. Urvan earned fees of $202,000 in cash and received stock awards valued at $162,600, for a total compensation of $364,600. On November 3, 2022, the Company entered into the 2022 Urvan Settlement Agreement with Mr. Urvan and Susan T. Lokey, pursuant to which the Company agreed to immediately increase the size of the Board from seven to nine directors and appoint specified directors to the Board. On May 21, 2025, the Company entered into the 2025 Urvan Settlement Agreement with Mr. Urvan and other parties, pursuant to which Mr. Urvan was appointed as Chief Executive Officer and Chairman of the Board effective May 30, 2025. As partial consideration for the 2025 settlement, the Company issued to an affiliated designee of Mr. Urvan a warrant to purchase 7.0 million shares of Common Stock with a five-year term and an exercise price of $1.81 per share, an unsecured promissory note in a principal amount of $12.0 million bearing interest at 6.50% per annum, and an unsecured promissory note in a principal amount of $39.0 million bearing interest at the applicable federal rate for long-term loans.